Here's How Moderna Plans to Beat the Biggest Threat to Its Vaccine
Moderna's (NASDAQ: MRNA) vaccine is successfully helping people avoid the coronavirus. The billion-dollar product has demonstrated more than 90% efficacy in adults. And new data show it's 100% effective in teens. But Moderna faces one big challenge that could wreak havoc on how well its vaccine protects the population. And that's the rapid emergence of variants.
The vaccine has handled them so far. Moderna even says one of its booster candidates may be ready by fall. One of the candidates specifically targets the South African variant. But the biotech company realizes it can't constantly chase the next variant. It has to stay a step ahead. Let's take a closer look at how Moderna plans to do that -- and what it means for investors.
Image source: Getty Images.
Source Fool.com
